drugset / Trial / NCT03500224

A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants

NCT03500224

Phase 1 Completed 6 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to determine the mass balance, routes of elimination and characterize the metabolic profiles of a single intravenous dose of \[14C\]-TAK-954, identify major circulating and excreted metabolites. This study will also determine the single-dose PK of total radioactivity, TAK-954 and its metabolites where possible.

Timeline

Start
2018-04-30
Primary completion
2018-06-01
Completion
2018-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject felcisetrag Small molecule 0.5 mg Intravenous

Indications

No indication recorded.